2nd Quarter - Report

ASTELLAS PHARMA US, INC. for ASTELLAS PHARMA US, INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$430,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 20, 2017 $430,000 Replaced
2nd Quarter - Amendment Dec 14, 2017 $570,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
MELISSA WIER BANASHAK —
SARAH CHRISTINE D'ORSIE —
MARY LACEY REUTHER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
MELISSA WIER BANASHAK —
SARAH CHRISTINE D'ORSIE —
MARY LACEY REUTHER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1409 (115th)

Medicare/Medicaid MMM

Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
MELISSA WIER BANASHAK —
SARAH CHRISTINE D'ORSIE —
MARY LACEY REUTHER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 849 (115th), S.J.Res. 16 (115th), S. 260 (115th), H.J.Res. 51 (115th), S. 251 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.